Victor L Perez

Prof. Victor L Perez


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
JPJonathan C. Poe
Jonathan C. Poe
WJWei Jia
Wei Jia
JPJulie A. Di Paolo
Julie A. Di Paolo
NRNancy J. Reyes
Nancy J. Reyes
JKJi Yun Kim
Ji Yun Kim
SSStefanie Sarantopoulos
Stefanie Sarantopoulos
Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (ENTO) is a second-generation highly selective SYK inhibitor with a high safety profile. Potential utility of ENTO as GVHD prophylaxis in patients was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. We found that early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Infiltrating SYK + cells expressing B220 or F4/80, resembling SYK + cells found in lichenoid skin lesions of chronic GVHD patients, were abundant in the skin of placebo mice but were rare in ENTO-treated mice. Thus, ENTO given early after HCT safely prevented GVHD.

23 September 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
VPVictor L Perez
Victor L Perez
HMHazem M. Mousa
Hazem M. Mousa
MSMatias Soifer
Matias Soifer
CBCole Beatty
Cole Beatty
SSStefanie Sarantopoulos
Stefanie Sarantopoulos
RLRobert B. Levy
Robert B. Levy

27 April 2022 in The Ocular Surface
Verified
Journal Article
Closed access
MSMatias Soifer
Matias Soifer
ATArianna Tovar
Arianna Tovar
MWMargaret Wang
Margaret Wang
HMHazem M. Mousa
Hazem M. Mousa
SYSowmya Yennam
Sowmya Yennam
VPVictor L Perez
Victor L Perez

21 July 2023 in Frontiers in Toxicology
Verified
Journal Article
Open access
RRRaul E. Ruiz-Lozano
Raul E. Ruiz-Lozano
NANadim S. Azar
Nadim S. Azar
HMHazem M. Mousa
Hazem M. Mousa
MQManuel E. Quiroga-Garza
Manuel E. Quiroga-Garza
SKSeitaro Komai
Seitaro Komai
VPVictor L Perez
Victor L Perez
Ocular surface disease (OSD), a disorder affecting the lacrimal and meibomian glands and the corneal and conjunctival epithelium, is a well-known complication of topical glaucoma therapy. OSD can present as a new or pre-existing condition that virtually any anti-glaucoma formulation can exacerbate. As such, both glaucoma and OSD frequently coexist. Typical OSD symptoms include ocular discomfort, redness, burning, and dryness, whereas signs include periorbital and eyelid skin pigmentation, conjunctival scarring, and superficial punctate keratitis. Pressure-lowering eyedrops can cause toxic, allergic, and inflammatory reactions on the ocular surface. The latter can result from either preservatives or direct toxicity from the active molecule. Although usually mild, OSD can cause significant symptoms that lead to poor quality of life, decreased compliance to therapy, glaucoma progression, and worse visual outcomes. Given the chronic nature of glaucoma, lack of curative therapy, and subsequent lifelong treatment, addressing OSD is necessary. This manuscript aims to provide an up-to-date overview of OSD’s signs, symptoms, and pathogenic mechanisms from glaucoma therapy toxicity.

1 January 2021 in The Ocular Surface
Verified
Journal Article
Closed access
MSMatias Soifer
Matias Soifer
HMHazem M. Mousa
Hazem M. Mousa
SSSandra S. Stinnett
Sandra S. Stinnett
AGAnat Galor
Anat Galor
VPVictor L Perez
Victor L Perez

16 February 2021 in Experimental Eye Research
Verified
Journal Article
Closed access
HMHazem M. Mousa
Hazem M. Mousa
DSDaniel R. Saban
Daniel R. Saban
VPVictor L Perez
Victor L Perez